US Patent 9,895,422: Claim Scope, Patent Expiration, Orange Book Status, and Generic-Entry Risk
US Patent 9,895,422 covers combination treatment of metabolic disorders using a dopamine receptor agonist and a first-phase insulin secretagogue. Its central limitations are pharmacodynamic synergy, morning or circadian administration of the dopamine agonist in certain claims, daily exposure to the insulin secretagogue, and treatment of glucose intolerance, insulin resistance, Type 2 diabetes, obesity, and related metabolic abnormalities.
The patent is a method-of-treatment patent. It does not claim bromocriptine, GLP-1 drugs, DPP-4 inhibitors, meglitinide products, or insulin compositions as chemical entities. Its commercial relevance depends on whether a competing product or treatment protocol practices the combination, timing, dosage, and therapeutic-effect limitations recited in an asserted claim.
What does US Patent 9,895,422 claim?
The independent claims cover three related treatment concepts:
| Claim |
Core combination |
Timing limitation |
Disease scope |
Key additional limitation |
| 1 |
Dopamine receptor agonist plus first-phase insulin secretagogue |
Dopamine activity timed to the natural circadian peak |
Metabolic disorder or key element |
Combination must produce more than an additive therapeutic effect |
| 2 |
D2 agonist plus first-phase insulin secretagogue |
Dopamine activity timed to circadian peak |
Glucose intolerance or insulin resistance |
D2 agonist must have low or no 5-HT2B agonist activity |
| 3 |
Dopamine receptor agonist plus first-phase insulin secretagogue |
Both administered so an effective amount is present daily |
Metabolic disorder or key element |
Greater-than-additive therapeutic effect |
| 16 |
Daily dopamine receptor agonist plus first-phase insulin secretagogue |
Daily administration |
Metabolic disorder or key element |
Greater-than-additive therapeutic effect |
Claims 5 through 7, 17 through 19 define the covered disorders and disease elements. Claims 8 and 9 narrow morning administration to within four hours, and then within two hours, of waking. Claims 10 through 12 address dose dependence and synergy. Claims 13 and 15 expand the dopamine agonist category.
The patent therefore has two principal claim architectures:
- A combination-treatment claim requiring circadian or morning administration.
- A combination-treatment claim requiring daily administration but not expressly requiring morning dosing.
The second architecture is potentially broader in timing but remains subject to the synergy requirement.
What drugs fall within the claimed combination?
The first-phase insulin secretagogue category is unusually broad. It includes:
- GLP-1 and GLP-1 analogs;
- DPP-4 inhibitors;
- Gastric inhibitory polypeptide, also called glucose-dependent insulinotropic peptide;
- Meglitinides;
- Repaglinide;
- Nateglinide, although the supplied claim text spells the term “nataglinide”;
- Postprandial insulin;
- Thiazolidinediones;
- Short-acting insulin.
The dopamine agonist category is also broad. The claims expressly identify:
- Bromocriptine;
- Lisuride;
- Hydergine;
- Dihydroergotoxine;
- Quinpirole;
- Quinerolane;
- Talipexole;
- Ropinirole;
- Apomorphine;
- Terguride;
- Fenoldopam;
- Dihydroergocryptine;
- Combinations of dopamine D1 and D2 receptor agonists.
Claim 2 is narrower because it requires a dopamine D2 receptor agonist with low or no serotonin 2B receptor agonist activity. Claims 4 and 13 provide specific or functional dopamine-agonist limitations that may affect infringement and validity analysis.
How broad is the patent’s practical scope?
The literal scope is broad, but practical enforcement is narrower.
A claimant would generally need to establish that the accused regimen includes:
- A dopamine receptor agonist.
- One of the listed first-phase insulin secretagogues.
- Administration to a patient with a covered metabolic condition.
- The required dosing schedule.
- A therapeutic effect greater than the additive effects of the two agents administered separately at the same dosages.
The fifth element is the principal evidentiary constraint. A combination does not necessarily infringe merely because both drugs are prescribed together. The patentee would need to show that the regimen produces a synergistic or greater-than-additive effect as claimed.
Claims 10 and 11 introduce a further limitation: one component may be administered at a dose that is insufficient to treat the disorder alone, while the combination produces the therapeutic effect. Claim 14 similarly requires that the effective dose of the secretagogue in combination be lower than the effective dose without the dopamine agonist.
These limitations create a distinction between:
- Mere co-administration;
- Additive pharmacology; and
- Claimed supra-additive or synergistic efficacy.
A generic or branded competitor may reduce infringement exposure by using different timing, making no combination efficacy representation, or relying on evidence that the two components are independently effective at the relevant doses. Those strategies do not eliminate all risk because infringement can be based on the treatment protocol promoted or directed by the product sponsor.
What formulations are protected by US 9,895,422?
US 9,895,422 does not principally claim a specific tablet, injectable formulation, extended-release formulation, excipient system, or fixed-dose combination composition. The claims are directed to administration methods.
The patent can nevertheless affect formulation strategy where the formulation controls:
- Morning release of the dopamine agonist;
- Daily exposure to the insulin secretagogue;
- Postprandial exposure;
- Circadian delivery;
- Dose reduction made possible by the combination; or
- Simultaneous or coordinated administration.
A formulation that merely contains bromocriptine is not necessarily within the claims. The infringement question turns on the labeled or practiced treatment method, including the second active agent and the timing of administration.
How important is the circadian dosing limitation?
Circadian dosing is central to claims 1, 2, 8, and 9.
Claim 1 requires administration of the dopamine agonist so that central dopaminergic activity increases at the time of day when the relevant circadian rhythm naturally peaks in healthy subjects of the same species. Claim 8 narrows the human regimen to primarily within four hours of waking, and claim 9 narrows it to within two hours of waking.
This limitation is closely associated with quick-release morning bromocriptine therapy. The FDA-approved Cycloset label describes once-daily morning administration within two hours of waking for Type 2 diabetes treatment.[1]
The timing limitation creates both value and vulnerability:
- It gives the patent a clinically specific regimen rather than an unrestricted combination claim.
- It may limit infringement by products labeled for evening, continuous, or non-circadian administration.
- It creates claim-construction issues concerning “primarily,” “within four hours,” “within two hours,” and the biological meaning of a circadian peak.
- It may require expert testimony on central dopaminergic activity and normal circadian physiology.
Claims 3 and 16 do not contain the same express morning limitation. They require daily effective amounts and supra-additive therapeutic activity. These claims may remain relevant where a competitor avoids morning dosing but promotes daily combination therapy.
What diseases and patient populations are covered?
The disease definitions extend well beyond Type 2 diabetes. The claims cover:
- Prediabetes;
- Impaired fasting glucose;
- Impaired glucose tolerance;
- Insulin resistance;
- Hyperinsulinemia;
- Metabolic syndrome;
- Obesity;
- Hyperglycemia;
- Hyperlipidemia;
- Hypertension;
- Atherosclerosis;
- Cardiovascular disease;
- Hepatic steatosis;
- Renal disease;
- Cerebrovascular disease;
- Congestive heart failure;
- Increased visceral fat;
- Elevated triglycerides and free fatty acids;
- Reduced HDL cholesterol;
- Vascular endothelial dysfunction;
- Oxidative stress;
- Hypercoagulability.
This breadth increases the potential number of covered clinical uses. It also raises written-description, enablement, and written-support issues. A challenger may argue that the specification does not adequately support every listed disease, every dopamine agonist, every insulin secretagogue, and every claimed synergistic combination across the full scope.
What are the main validity risks?
Written description and enablement
The claims cover numerous drug classes and disease conditions. The broader the claim, the greater the question whether the specification demonstrates possession of the full genus and enables the full combination set.
Potential pressure points include:
- Whether the specification supports synergy for every listed secretagogue;
- Whether evidence for bromocriptine supports unrelated agonists such as ropinirole or apomorphine;
- Whether a metabolic benefit shown in Type 2 diabetes supports cardiovascular, renal, cerebrovascular, and hepatic indications;
- Whether “greater than additive” is sufficiently measurable;
- Whether “central dopaminergic activity” can be determined consistently in clinical practice.
Indefiniteness
The following phrases may attract claim-construction challenges:
- “Greater than the additive effect”;
- “Key elements of a metabolic disorder”;
- “Primarily within 4 hours of waking”;
- “Low or no serotonin 2B receptor agonist activity”;
- “Effective amount”;
- “The time of day its circadian rhythm naturally peaks.”
The claims may survive if the specification supplies testing methods and clinical standards. The absence of a defined synergy assay or a quantitative threshold would strengthen an indefiniteness challenge.
Obviousness
A challenger could combine prior art concerning:
- Dopamine agonists and glucose regulation;
- Bromocriptine and Type 2 diabetes;
- GLP-1 therapy or DPP-4 inhibition;
- Circadian metabolic regulation;
- Combination treatment for insulin resistance.
The strongest obviousness defense would depend on evidence that the combination produced an unexpected supra-additive effect and that morning administration generated a clinically meaningful result not predicted by the prior art.
What is the FDA and Orange Book relevance?
Cycloset is the most direct FDA product associated with the patent’s dopamine-agonist strategy. It is bromocriptine mesylate, a quick-release oral product indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.[1]
The Orange Book distinction is important:
- An Orange Book listing attaches to an approved NDA and identifies patents that claim the drug, an approved method of using the drug, or a drug product.
- A patent may be relevant to a product without appearing in the Orange Book.
- Method-of-use patents are generally listed only when the NDA holder submits them and the FDA accepts the listing.
- A patent covering a combination of bromocriptine with another class may not be listed against a monotherapy NDA unless the approved labeling practices the claimed combination.
A definitive Orange Book conclusion requires the specific FDA listing record for the relevant NDA and product. The patent number alone does not establish Orange Book listing status.[2]
When does US 9,895,422 lose exclusivity?
Patent expiration is determined by the earliest effective nonprovisional filing date for the relevant family, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable disclaimer or correction. Patent term is generally 20 years from the earliest effective nonprovisional filing date for applications filed after June 8, 1995.[3]
The issue date of February 20, 2018, does not determine expiration. A continuation patent can issue years after the start of the family term and still expire on the parent family’s term date.
The principal exclusivity timeline is therefore:
| Event |
Relevance |
| Earliest family nonprovisional filing |
Starts the ordinary 20-year patent term |
| Patent issuance on February 20, 2018 |
Creates enforceable issued claims, subject to the term already running |
| FDA approval of Cycloset in 2009 |
Creates regulatory approval for bromocriptine therapy, not automatic exclusivity for every patent claim |
| Patent-term adjustment or extension |
May move the expiration date |
| Orange Book listing |
Can support a Paragraph IV notice and statutory stay if the listed patent covers the approved product or use |
The family’s precise expiration must be taken from the USPTO patent record and any terminal-disclaimer or patent-term-adjustment data. It should not be inferred from the 2018 issue date.
Are Paragraph IV challenges likely?
A Paragraph IV certification is relevant only if the patent is listed in the Orange Book for the drug product involved. For a listed method-of-use patent, a generic applicant may certify that the patent is invalid, unenforceable, or will not be infringed, or may submit a section viii statement carving out the patented use from its labeling.[4]
Potential Paragraph IV targets include:
- A generic bromocriptine product seeking the Cycloset indication;
- A product seeking approval for a combination use involving bromocriptine and another insulin-regulating agent;
- A product whose proposed labeling instructs morning administration within two hours of waking.
A generic label that omits the claimed combination or circadian regimen may reduce induced-infringement exposure. The risk increases if the reference product’s labeling expressly directs combination use with GLP-1 therapy, DPP-4 inhibitors, insulin, or other listed agents.
Which companies face the greatest competitive exposure?
The direct exposure is highest for companies commercializing:
- Bromocriptine products for Type 2 diabetes;
- Combination diabetes products involving bromocriptine;
- GLP-1 or DPP-4 products marketed with bromocriptine;
- Digital or clinical protocols that instruct morning dopamine-agonist dosing;
- Fixed-dose or co-packaged metabolic therapies.
Large diabetes companies with GLP-1, DPP-4, insulin, or thiazolidinedione products could face method-use issues only if their labeling or promotional activity directs the patented combination. A company selling one component without directing combination use generally presents a weaker inducement case.
How strong is the patent estate?
The estate is strongest in the following areas:
- Morning or circadian bromocriptine treatment combined with a glucose-lowering agent.
- Daily dopamine-agonist and insulin-secretagogue therapy.
- Dose-reduction strategies based on combination synergy.
- Treatment of impaired glucose tolerance, insulin resistance, and Type 2 diabetes.
The estate is weaker where:
- The accused therapy uses a dopamine agonist not supported by clinical data;
- The product is administered outside the claimed timing window;
- The regimen does not demonstrate supra-additive efficacy;
- The label does not direct combination use;
- The claim is challenged for written-description or enablement deficiency across its broad drug and disease genera.
The patent creates a method-of-use barrier, not a blanket barrier to generic bromocriptine, GLP-1, DPP-4, insulin, or meglitinide products.
What generic launch scenarios exist?
Scenario 1: Stand-alone generic bromocriptine
Risk is moderate to low if the generic label omits the patented combination and circadian method. Risk rises if the label mirrors the Cycloset morning regimen and the Orange Book includes the patent.
Scenario 2: Generic bromocriptine with Type 2 diabetes labeling
Risk depends on the approved indication, label wording, and patent listing. A label directed to morning use within two hours of waking could practice claims 8 and 9.
Scenario 3: GLP-1 or DPP-4 product marketed for add-on use with bromocriptine
Risk is higher if promotional materials recommend the specific combination and claim synergistic efficacy. The combination must still satisfy the patent’s greater-than-additive limitation.
Scenario 4: Off-label physician combination
Physician prescribing alone does not automatically establish liability by a manufacturer. The central issue is whether the manufacturer encourages or directs the infringing method through labeling, marketing, training, or other conduct.
Key Takeaways
- US 9,895,422 is a broad method-of-treatment patent covering dopamine agonists combined with first-phase insulin secretagogues.
- Bromocriptine is the commercially central dopamine agonist.
- The claims cover GLP-1 agents, DPP-4 inhibitors, meglitinides, insulin, thiazolidinediones, and related therapies.
- Claims 1, 2, 8, and 9 impose morning or circadian timing limitations.
- Claims 3 and 16 are broader in timing but require daily effective amounts and greater-than-additive therapeutic effect.
- Claims 10, 11, and 14 create dose-reduction and combination-dependence limitations.
- The principal litigation issues are synergy, claim construction, enablement, written description, obviousness, and induced infringement.
- The patent does not block generic products used alone.
- Orange Book significance depends on the specific NDA listing and approved labeling.
- Patent expiration must be calculated from the earliest effective family filing date, not the 2018 issue date.
- Generic launch risk is highest when a label directs bromocriptine use in the morning together with a listed insulin-secretagogue class.
FAQs
Does US 9,895,422 cover bromocriptine itself?
No. The patent claims treatment methods using bromocriptine and other dopamine agonists in combination with specified insulin-secretagogue therapies.
Can a generic DPP-4 inhibitor infringe this patent?
Potentially, but only if the relevant labeling or conduct directs administration with a covered dopamine agonist and the other claim limitations are satisfied.
Does taking bromocriptine and insulin on the same day infringe?
Not necessarily. The claims require a covered therapeutic combination and, in most independent claims, a greater-than-additive therapeutic effect.
Does evening administration avoid the patent?
It may avoid claims requiring morning or circadian administration, but it may not avoid claims requiring daily administration under claims 3 and 16.
Is this patent relevant to GLP-1 drugs such as semaglutide?
Potentially. GLP-1 or an analog is expressly included in the claimed first-phase insulin-secretagogue category. Infringement would still require the dopamine agonist, covered disease, dosing, and supra-additive-effect limitations.
References
- U.S. Food and Drug Administration. (2009). Cycloset (bromocriptine mesylate) tablets prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure § 2701: Patent term.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications, 21 C.F.R. § 314.101 and § 314.107.
- United States Congress. (2024). 35 U.S.C. §§ 101, 102, 103, 112, 154, and 271.
- U.S. Patent No. 9,895,422. (2018). Methods of treating metabolic disorders. United States Patent and Trademark Office.
